CING EBITDA | Cingulate Inc.

Cingulate Inc. (CING) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$5.41M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$7.92M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$6.00M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$4.65M; Depreciation and amortization (m).

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$5.41M	(m)	(m)	(m)	$67.08K*	-$5.90M*	(m)	$1.49M	$3.93M	(m)
2026-03-31	Reported	(m)	-$7.92M	(m)	(m)	(m)	$61.18K	-$6.91M	(m)	$2.18M	(m)	(m)
2025-09-30	Reported	(m)	-$6.00M	(m)	(m)	(m)	$0.00*	-$4.24M*	(m)	$2.85M	(m)	(m)
2025-06-30	Reported	(m)	-$4.65M	(m)	(m)	(m)	(m)	-$4.80M*	(m)	$2.70M	$1.95M	(m)
2025-03-31	Reported	(m)	-$3.71M	(m)	(m)	(m)	(m)	-$4.61M	(m)	$2.22M	(m)	(m)
2024-09-30	Reported	(m)	-$3.28M	(m)	(m)	(m)	-$140.79K*	-$3.88M*	(m)	$1.43M	(m)	(m)
2024-06-30	Reported	(m)	-$3.21M	(m)	(m)	(m)	$72.63K*	-$1.74M*	(m)	$1.88M	(m)	(m)
2024-03-31	Reported	(m)	-$2.95M	(m)	(m)	(m)	$81.51K	-$8.75M	(m)	$1.81M	(m)	(m)
2023-09-30	Reported	(m)	-$5.75M	(m)	(m)	(m)	$0.00*	-$4.29M*	(m)	$3.92M	(m)	(m)
2023-06-30	Reported	(m)	-$6.36M	(m)	(m)	(m)	$1.00*	-$4.60M*	(m)	$4.46M	(m)	(m)
2023-03-31	Reported	(m)	-$3.85M	(m)	(m)	(m)	$37.13K	-$3.58M	(m)	$2.13M	(m)	(m)
2022-09-30	Reported	(m)	-$3.97M	(m)	(m)	(m)	$0.00*	-$3.40M*	(m)	$2.12M	(m)	(m)
2022-06-30	Reported	(m)	-$4.05M	(m)	(m)	(m)	$0.00*	-$4.41M*	(m)	$2.18M	(m)	(m)
2022-03-31	Reported	(m)	-$5.01M	(m)	(m)	(m)	$10.40K	-$3.86M	(m)	$2.76M	(m)	(m)
2021-09-30	Reported	(m)	-$15.28M	(m)	(m)	(m)	$15.77K*	-$2.59M*	(m)	$5.79M	(m)	(m)
2021-06-30	Reported	(m)	-$1.42M	(m)	(m)	(m)	$22.49K*	-$1.55M*	(m)	$793.59K	(m)	(m)
2021-03-31	Reported	(m)	-$1.33M	(m)	(m)	(m)	$66.47K	-$1.67M	(m)	$562.52K	(m)	(m)

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$19.94M	(m)	(m)	(m)	$162.14K	-$17.25M	(m)	$9.77M	(m)	(m)
2024-12-31	Reported	(m)	-$15.64M	(m)	(m)	(m)	$211.80K	-$18.45M	(m)	$9.45M	(m)	(m)
2023-12-31	Reported	(m)	-$22.76M	(m)	(m)	(m)	$224.10K	-$15.03M	(m)	$15.49M	(m)	(m)
2022-12-31	Reported	(m)	-$17.50M	(m)	(m)	(m)	$153.42K	-$15.88M	(m)	$9.00M	(m)	(m)
2021-12-31	Reported	(m)	-$20.68M	(m)	(m)	(m)	$814.74K	-$10.43M	(m)	$8.41M	(m)	(m)
2020-12-31	Reported	(m)	-$7.08M	(m)	(m)	(m)	$402.10K	-$6.81M	(m)	$5.09M	(m)	(m)

Stock Name	Country	Market Cap	PE Ratio
Spero Therapeutics, Inc. (SPRO)	United States	$0.073B	17.41
Aldeyra Therapeutics, Inc. (ALDX)	United States	$0.074B	-5.57
Lunai Bioworks Inc. (LNAI)	United States	$0.072B	-0.11
PMV Pharmaceuticals, Inc. (PMVP)	United States	$0.071B	-0.95
TENAX THERAPEUTICS, INC. (TENX)	United States	$0.071B	-7.17
PLIANT THERAPEUTICS, INC. (PLRX)	United States	$0.071B	-0.76
OS Therapies Inc (OSTX)	United States	$0.076B	-2.17
Yarrow Bioscience, Inc. (YARW)	United States	$0.070B
Verrica Pharmaceuticals Inc. (VRCA)	United States	$0.076B	-3.39
iBio, Inc. (IBIO)	United States	$0.077B	-2.94